Summary. The nuclear data required for the production and endotherapeutic application of radionuclides are outlined. The three types of therapeutic radionuclides, viz. β − -emitters, α-emitters and Auger electron emitters, are considered and the role of some β + -emitters in therapy planning is discussed.
Introduction
Radiation therapy has gained an important place in medicine. It is mostly performed using external beams of electrons, X-rays, γ -rays from radioactive sources (e.g. 60 Co), highenergy γ -rays from accelerators, or hadrons (neutrons, protons, heavy ions, etc.). The use of electrons and photons constitutes conventional therapeutic practice, and the data needed are well documented. The rationale of hadron therapy and the associated data needs are treated well in this issue (cf. contributions by Jones, Wambersie, Haight, and Chadwick).
In addition to external radiation therapy, some radioisotopes are used internally to achieve the therapeutic effect. This could involve introducing a radioisotope in a given part of the body (e.g. joints, organ, tumour, etc.) either mechanically or via a biochemical pathway. The mechanical introduction takes place through injection of conglomerates or colloids (e.g. in joints) or as solids in the form of seeds or stents. This form of therapy is often known as brachytherapy. The use of a biochemical pathway to deliver a therapeutic radioisotope to a specific organ is termed as endoradiotherapy. This type of radiotherapy is a unique cancer treatment modality. It is systemic and non-invasive. The uptake and retention in the tumour can be assessed with a tracer study prior to administering a therapeutic dose. On the other hand, there are also several associated problems, such as, the exact range of the ionising radiation, the in vivo stability of the radiotherapeutical, the possibility of immuno chemical changes, etc. Many aspects of endoradiotherapy have been discussed [cf. Refs. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . In this article, the nuclear data aspect is treated in some detail.
*E-mail: s.m.qaim@fz-juelich.de
Criteria for choice of a radionuclide for therapeutic studies
The major criteria for the choice of a radionuclide for endotherapeutic use are suitable decay characteristics and suitable biochemical reactivity. As regards decay properties, the desired half-life is between 6 h and 7 d and the emitted corpuscular radiation should have a suitable linear energy transfer (LET) value and range in the tissue. The ratio of non-penetrating to penetrating radiation should be high. The daughter should be short-lived or stable. As regards biochemical reactivity, the situation is similar to that for diagnostic radiopharmaceuticals. However, the stability of the therapeutical is demanded over a much longer period than that in the case of a diagnostic pharmaceutical. The basis for successful endoradiotherapy thus incorporates (i) Good and selective concentration and prolonged retention of the radiotherapeutical in the tumour, and (ii) Minimum uptake in normal tissue.
As a result of the above mentioned criteria, the choice falls on about 30 radionuclides. Most of them are β − -emitters but several of them are α-and Auger electron emitters. In recent years a few β + -emitters have also found some limited therapeutic application.
Radioactive decay data
The half-life (i.e. the physical half-life) of a radioisotope is important. However, in endoradiotherapy of greater importance is the biological half-life, which determines the retention of the radiotherapeutical in the organ. The physical half-life is generally well known; the biological half-life needs to be determined for each individual system via tracer experiments.
The ranges of various types of emitted corpuscular radiation in the tissue are shown in Fig. 1 [cf. 8, 11] . The Auger electrons have a range of about 10 µm and can have a therapy effect only if they reach the cell nucleus, e.g. by bringing the radioactive source atom to the DNA. The α-particles, on the other hand, have a range of about 100 µm and can have a therapy effect already if they reach the cell membrane, e.g. by attachment of the α-emitter to a receptor ligand. The β − -particles have ranges of about 1 mm and more, depending upon their energies. They can lead to therapy effects even if they reach the cell environment. Evidently, achieving the therapy effect with Auger electrons and α-particles involves a very subtle approach and demands great skills in biochemistry, radiopharmacology and radiotherapeutical production and application. In the case of β − -particles, the therapeutic applications have been more straightforward, though not very specific.
The methods of internal dose calculation have received extensive attention and well-known computer codes, known as MIRD codes, are now available. As regards diagnostic radionuclides, calculations are done to keep the radiation dose as low as possible. In the case of therapeutic radionuclides, on the other hand, the dose has to be high enough to achieve the therapeutic effect.
In endoradiotherapy, the radioactive decay data thus play a very important role (see also [4, 8] ). In particular, a knowledge of the energy and intensity of the ionising radiation is crucial. The effect of low-energy but high intensity electrons, emitted following EC and IT, is not negligible. For widely used therapeutic radioisotopes therefore all sources of secondary electrons must be taken into account. The accuracy in dosimetry depends on the accuracy of the available decay and biochemical data. In general, the available decay database is extensive [cf. 12, 13] . The Auger electron spectra, on the other hand, are often not accurately known.
Production data
The criteria for the production of therapeutic radioisotopes are generally the same as those for diagnostic radioisotopes, i.e. high radionuclidic purity, high radiochemical purity and high specific radioactivity (cf. contribution by Qaim, this issue). The three types of therapeutic radionuclides, viz. β − -emitters, α-emitters and Auger electron emitters, are treated below separately.
β − -emitters
The number of β − -emitters of therapeutic relevance is relatively large. The commonly used radionuclides are listed in Table 1 . In each case the main decay and production data are outlined. To date, 131 I has been most extensively utilized, but in recent years many of the other isotopes listed in Table 1 have been finding enhanced application.
Besides the commonly used β − -emitters, several other β − -and β + -emitters have found isolated therapeutic applications. A few examples of β − -emitters are: − -emitters are produced in a nuclear reactor, and data are needed on neutron capture, sequential neutron capture, (n, z) processes and fission yields. Some special radionuclides like 67 Cu and 186 Re are produced using both a reactor and an accelerator.
In a nuclear reactor, the (n, γ ) process is commonly utilized for production purposes. The excitation function of a typical (n, γ ) reaction is shown in Fig. 2 [cf. 14]. The major interest is in the low energy region. The specific radioactivity achieved is rather low. In general, it is limited by the cross section of the (n, γ ) reaction, the isotopic abundance of the target isotope and the neutron flux in the reactor. With a view to enhancing the specific radioactivity, either the β − -decay daughter of an (n, γ )-product is used, e.g.
110 Pd(n, γ ) 111m,g Pd → 111 Ag, or a generator system is developed, e.g. 90 Sr → 90 Y and 188 W → 188 Re. Occasionally an alternative route of production is looked for. This may involve the use of an (n, p) reaction in a fast neutron field or the utilization of a cyclotron. The two aspects are considered individually below.
The (n, p) reaction is occasionally utilized to produce therapeutic radionuclides in the medium and heavy mass regions, besides its use in the light mass region. Two demonstrated examples are 67 Zn(n, p) 67 Cu and 89 Y(n, p) 89 Sr. The product yield in a fission neutron spectrum is low, since the threshold of the (n, p) reaction is rather high, i.e. between 2 and 6 MeV. The excitation functions of the 67 Zn(n, p) 67 Cu and 89 Y(n, p) 89 Sr reactions, measured radiochemically [15, 16] , are shown in Fig. 3 . If an intense fast neutron field is used, the cross section averaged over the whole spectrum is much higher than for a fission spectrum. A suitable example is the breakup neutron field, produced by 14-15 MeV deuterons on beryllium [cf. 17]. Since presently available high-intensity commercial machines are capable of providing such fast neutron fields, the production of 67 Cu and 89 Sr via the respective (n, p) reaction appears very advantageous. Another possibility is the use of a spallation a: Neutron capture data are for thermal neutrons and the (n, p) cross sections are fission neutron spectrum averaged values. The fission yields are cumulative yields (Y cum ). b: For charged particle induced reactions the cross section at a suitable energy is given. c: For this reaction the full excitation function has been measured. neutron source, generated by high energy protons on a heavy target. In the spectrum, there is a sufficiently strong fast neutron component (with E n ≥ 10 MeV), which is ideally suited for (n, p) reactions. Besides 67 Cu and 89 Sr, several other therapeutic radioisotopes like 47 Sc, 77 As, 105 Rh, 153 Sm, 159 Gd, 166 Ho, 177 Lu, 188 Re, etc. could also be produced in fast neutron fields via (n, p) reactions on enriched target isotopes. In recent years attempts have been underway to utilize small and medium-sized cyclotrons to produce some known β − -emitting therapeutic radionuclides via alternative routes as well as to develop other radionuclides of potential therapeutic interest. Two important examples are furnished by 67 Cu and 186 Re. 67 Cu is almost an ideal therapeutic radionuclide. It is produced via an (n, p) reaction in a nuclear reactor (see above), via the spallation of RbBr or via the 68 Zn( p, 2 p) reaction at a high energy accelerator [cf. 18, 19] . A recent study showed [20] that the 70 Zn( p, α) 67 Cu reaction over the proton energy range E p = 18 → 12 MeV, using highly enriched 70 Zn as target material, can be used to produce 67 Cu at a small cyclotron. The radionuclide 186 Re is produced generally via the 185 Re(n, γ )-reaction. Since it forms very stable co-ordination compounds (similar to technetium), it has a great therapeutic potential. The main limitation is its specific radioactivity. Two alternative routes making use of the 186 W( p, n) 186 Re and 186 W(d, 2n) 186 Re reactions are therefore attracting great interest. The excitation functions have been measured [cf. [21] [22] [23] and the yields are known (cf. Fig. 4 ). The yield of 186 Re via the (d, 2n) reac- Fig. 4 . Calculated integral yields of 186 Re (T 1/2 = 3.8 d) formed via proton and deuteron induced reactions on 186 W. The relatively low yields of 186 Re suggest that the very long-lived high-spin isomer is produced in relatively high yields (adapted from [22] ). tion at 15 MeV is much higher than via the ( p, n) reaction at 19 MeV [cf. 22].
Despite the above mentioned four production approaches to increase the specific activity of a β − -emitter (viz. use of a β − -decay daughter of an (n, γ )-product, development of a generator system, application of an (n, p) reaction or use of a cyclotron), there are a large number of cases where there is no alternative to an (n, γ ) reaction. Most of those cases refer to rare-earth isotopes which, in recent years, have been attracting enhanced attention [cf. 24] due to their affinity for bone matrix. Fortunately, the (n, γ ) cross sections in that mass region are quite high, so that the specific radioactivity achieved is not as low as in many other cases. If an enriched target isotope and a higher flux reactor are used, the achievable specific radioactivity may still be enhanced.
α-emitters
The commonly used α-emitting radionuclides are listed in Table 1. 211 At is important and is produced via the (α, 2n) reaction on bismuth and the data are well known [cf. 25] . 225 Ac is a promising radioisotope, both in itself and as a generator for 213 Bi. It is obtained as a decay product of 229 Th, occurring in the nuclear waste. An interesting production route is the reaction 226 Ra( p, 2n) 225 Ac [cf. 26]. Its cross section has hitherto not been measured and constitutes a very challenging task. A few other potentially useful α-emitters are 149 Tb (
224 Ra (T 1/2 = 3.7 d), etc. The use of α-emitting radionuclides in endoradiotherapy has been under review almost ever since the discovery of radioactivity. In recent years it has gained more impetus. It should, however, be pointed out that the application of α-emitters demands stringent quality control tests. While working with 211 At, for example, a very careful check of the irradiation conditions is mandatory. The α-particle energy to induce the 209 Bi(α, 2n)-reaction is kept at 28.0 MeV otherwise the 209 Bi(α, 3n) 210 At reaction would also occur. Its decay product leads to the α-emitting 210 Po (T 1/2 = 138.4 d) and would cause excessive extra radiation dose. The field of radiotherapy with α-particles is expected to develop further. Consequently the need for both accurate decay and production data will increase.
X-ray and Auger electron emitters
Some of the X-ray and Auger electron emitters which have found therapeutic use are listed in Table 1 . Evidently, both reactors and cyclotrons are utilized for production purposes. However, the cyclotrons appear to have a higher potential since both X-ray and Auger electron emitters are generally neutron deficient.
The radioisotopes 67 Ga and 111 In are known more as diagnostic radionuclides since they emit suitable γ -rays. However, their potential as Auger electron emitting therapeutic radionuclides is being increasingly realized. Of particular interest is 125 I since it is almost a pure Auger electron emitter and is conveniently attached to a DNA molecule. The radionuclide 103 Pd has gained great significance in recent years. The production data were measured recently [cf. 27, 28] However, the presently used production methods ((n, γ ) and (n, n γ ) process) give very low yields of the latter two radioisotopes. Since in both cases high spin isomers are involved, the 3 Heand α-particle induced reactions may be advantageous. In general, Auger electron therapy has a great potential [cf. 30] but calls upon more fundamental work in all related areas.
The radionuclide 117m Sn (T 1/2 = 13.6 d) is interesting since here conversion electrons, instead of X-rays and Auger electrons, are effective in palliative therapy. Evidently, all data related to conversion electron emission would be needed for dose calculation. The radionuclide is produced via the (n, n γ )-process [cf. 31, 32 ]. An alternative method of production involves the 3 He-and α-particle induced reactions on In and Cd [33] .
Some special considerations in studies relevant to production data
Most of the special considerations in nuclear data studies related to the production of diagnostic radioisotopes (cf. contribution by Qaim, this issue), such as, the search for alternative production routes, the role of increasing incident particle energy, and the check of isomeric impurities, are valid also for the therapeutic radionuclides. Furthermore, cross section measurements relevant to the formation of pure β − -emitters and Auger electron emitters are often very challenging since very clean radiochemical separations and thin source preparation are required. The counting methods may involve low-level β − -counting, X-ray spectrometry or liquid scintillation counting. Thus interdisciplinary techniques are of great significance in these studies. 
Analogue positron emitters: therapy planning

Status of nuclear data and conclusions
As discussed above, most of the radionuclides commonly used in endoradiotherapy are β − -emitters. They are mainly produced in a nuclear reactor and the status of nuclear data is generally good [cf. [36] [37] [38] [39] . However, to date no evaluated data file in this respect has been developed. Regarding the β − -and β + -emitters which have hitherto found only limited application, or which are of potential interest, the cross section data base varies from case to case. For reactor-produced radionuclides it is good; for cyclotron produced radioisotopes, however, more work may be needed. In particular, an evaluation of the existing data is required. The available information on the established α-emitter 211 At is good. Similarly the decay and production data of the commonly used Auger electron emitters are well known. For potentially useful α-emitters and Auger electron emitters, however, the available information both on decay and production data is often not detailed enough. Since endoradiotherapy is a fast developing field, and new radionuclides emitting the latter two types of corpuscular radiation are being constantly suggested, the need for nuclear data is enhancing. Considerable amount of experimental, theoretical and evaluation work would be necessary to meet those needs. The experimental work is often very challenging since a quantitative measurement of the radioactivity via X-ray spectrometry or Auger electron counting is needed. Theory and evaluations face difficulties since isomeric states with highly converted isomeric transitions are involved. In the latter case, a detailed information on the conversion coefficients is also needed. In short, a concerted effort is called for to build a reliable database relevant to production and application of therapeutic radionuclides.
